PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT5688146

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	

CONVEYING PARTY DATA

Name	Execution Date
GLENMARK PHARMACEUTICALS LIMITED	08/26/2019

RECEIVING PARTY DATA

Name:	GLENMARK LIFE SCIENCES LIMITED	
Street Address: PLOT NO. 170-172, CHANDRAMOULI INDUSTRIAL ESTATE		
Internal Address:	MOHOL BAZARPETH	
City:	City: SOLAPUR	
State/Country:	tate/Country: INDIA	
Postal Code:	413213	

PROPERTY NUMBERS Total: 26

Property Type	Number
Application Number:	15754067
Application Number:	16070002
Patent Number:	7312329
Patent Number:	7649096
Patent Number:	7863273
Patent Number:	8097729
Patent Number:	8304544
Patent Number:	8334385
Patent Number:	8623844
Patent Number:	9056813
Patent Number:	9353114
Patent Number:	9440927
Patent Number:	9499475
Patent Number:	9518048
Patent Number:	9550735
Patent Number:	9567332
Patent Number:	9593119
Patent Number:	9663505
Patent Number:	9670160

PATENT REEL: 050179 FRAME: 0351

505641340

Property Type	Number
Patent Number:	9695159
Patent Number:	9776985
Patent Number:	9840456
Patent Number:	10106483
Patent Number:	10125115
Patent Number:	10138190
Patent Number:	10138206

CORRESPONDENCE DATA

Fax Number: (631)393-6271

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 6313936270

Email: NYOFFICE@RML-LAW.COM

Correspondent Name: MICHAEL E. CARMEN

Address Line 1: RYAN, MASON & LEWIS, LLP

Address Line 2: 48 SOUTH SERVICE ROAD, SUITE 100

Address Line 4: MELVILLE, NEW YORK 11747

ATTORNEY DOCKET NUMBER:	1276-0
NAME OF SUBMITTER: MICHAEL E. CARMEN	
SIGNATURE:	/Michael E. Carmen/
DATE SIGNED:	08/27/2019

Total Attachments: 4

source=Assignment_ScheduleA_2019_#page1.tif source=Assignment_ScheduleA_2019_#page2.tif source=Assignment_ScheduleA_2019_#page3.tif source=Assignment_ScheduleA_2019_#page4.tif

> PATENT REEL: 050179 FRAME: 0352



Partnership, Innovation, Passion.

ASSIGNMENT

For good and valuable consideration, the receipt of which is hereby acknowledged, GLENMARK PHARMACEUTICALS LIMITED ("Assignor"), does hereby sell, assign, transfer and convey unto GLENMARK LIFE SCIENCES LIMITED, having its registered office at Plot No. 170-172, Chandramouli Industrial Estate, Mohol Bazarpeth, Solapur 413213, India, ("Assignee") and to Assignee's successors, assigns and legal representatives or nominees as it may designate (collectively, hereinafter, "Assignee"), all of Assignor's entire right, title and interest in and to (a) all the United States patents and United States Patent Applications listed on the attached SCHEDULE; (b) all reissues, reexaminations, and extensions thereof; and (c) foreign counterparts to any or all of the foregoing, including without limitation utility models design patents, certificates of invention and equivalent rights worldwide; (collectively "Patent Rights"), and the entire right, title and interest, for the United States of America and its Territories and Commonwealth and Possessions, and for all other countries throughout the world, in and to all inventions and improvements disclosed in the intellectual property identified in the SCHEDULE attached hereto, and any additional patents that have issued or may issue or patent applications that have been filed or may be filed claiming priority to any of the patents or patent applications identified in the attached SCHEDULE, as well as the rights for all patents, divisions, reissues, re-examination certificates, continuing applications and extensions thereof, together with the right of priority of any earlier corresponding patent application filed by the undersigned in the United States or elsewhere.

In addition, Assignor agrees to and hereby does sell, assign, transfer and convey unto Assignce all rights (i) in and to causes of action and enforcement rights for the Patent Rights including all rights to pursue damages, injunctive relief and other remedies for past, present and future infringement of the Patent Rights, and (ii) the rights, if any, to revive prosecution of any abandoned or expired Patent Rights.

The Assignor covenant(s) that the rights and property conveyed by this Assignment are free and clear of any encumbrance, and that the Assignor has full right to convey the rights and property as expressed herein.

The Assignor authorize(s) and request(s) that any and all patents to be issued on the aforesaid patent applications be issued to Assignee.

The Assignor agrees, when requested, without further charge to Assignee but at its expense, to communicate to Assignee or its representatives all facts known to the undersigned regarding the aforesaid inventions and improvements, testify in any legal proceeding, sign all papers, make all rightful oaths or declarations, execute all divisional, continuing, re-examination and reissue applications and generally perform all acts, which may be necessary, desirable or convenient, to aid Assignee in securing, maintaining and enforcing patents for the aforesaid inventions and improvements in the aforesaid countries, and for vesting title thereto in Assignee.

Glenmark Life Sciences Limited

(Formerly known as Zorg Laboratories Private Limited)

Glenmark Life Sciences Research Centre, Plot No. A-607, T.T.C. Industrial Area, MIDC, Mahape, Navi Mumbai - 400 709, India

Registered Office: Plot No 170-172, Chandramouli Industrial Estate, Mohol Bazatpeth, Solaput - 413 213, India.

T: 91 22 5045 1290 CIN: U74900PN2011PLC139963 E: complianceofficer@glenmarklifesciences.com

PATENT

REEL 050179 FRAME: 0353

IN WITNESS WHEREOF this Assignment is executed on behalf of Assignor and Assignee as set forth below:

Glenmark Pharmaceuticals Limited (Assignor)

Date: 26 August, 2019

Date: 26 August, 2019

BA: (Ma_11,_1/2)

Name: Mr. Taranpreet Singh Lamba

Title: Vice President

Glenmark Life Sciences Limted (Assignee)

Ву:

Name: Dr. Madhavi Karnik

Title: Senior General Manager

SCHEDULE

Patent No.	Issue Date	Title
7,312,329	12-25-2007	Process for The Preparation of Pyrimidine Derivatives
7,649,096	01-19-2010	Process For The Preparation Of A Crystalline form of (S)-N [[3-(3-Fluoro-4- (4-Morpholinyl) Phenyl]-2-Oxo-5- Oxazolidinyl] Methyl] Acetamide
7,863,273	01-04-2011	Process for the Preparation of an Optically Active 5h-Pyrrolo [3,4-B] Pyrazine Derivative
8,097,729	01-17-2012	Polymorphic Form of Lercanidipine Hydrochloride and Process for the Preparation Thereof
8,304,544	11-06-2012	Palonosetron Free Base and Process for its Preparation
8,334,385	12-18-2012	Process For The Preparation of R-Sitagliptin and its Pharmaceutically Acceptable Salts Thereof
8,623,844	01-07-2014	Fosaprepitant Dimeglumine Intermediate, Neutral Fosaprepitant, and Amorphous Fosaprepitant Dimeglumine and Processes for Their Preparations
9,056,813	06-16-2015	Process for Preparation of Fingolimod
9,353,114	05-31-2016	Process For The Preparation of Dipeptidylpeptidase Inhibitors
9,440,927	09-13-2016	Process for Preparation of Substituted 3'- Hydroazino-Diphenyl-3-Carboxylic Acid Compounds
9,499,475	11-22-2016	Process for the Preparation of Arformoterol or Salt Thereof
9,518,048	12-13-2016	Process for the Preparation of Teneligliptin
9,550,735	01-24-2017	Process for the Preparation of Ivacaftor and Solvates Thereof
9,567,332	02-14-2017	Process for The Preparation and Purification of Apixaban
9,593,119	03-14-2017	Process for the Preparation of Dipeptidylpeptidase Inhibitors
9,663,505	05-30-2017	Process for the Preparation of Rivaroxaban
9,670,160	06-06-2017	Process for the Preparation of Tofacitinib and Intermediates Thereof
9,695,159	07-04-2017	Process for Preparation of Canagliflozin
9,776,985	10-03-2017	Process for Preparation of Alogliptin

1

Patent No.	Issue Date	Title
0.840.456	9,840,456 Process for Preparation of Dime Fumarate	Process for Preparation of Dimethyl
9,040,430		Fumarate
10,106,483	10-23-2018	Process for Preparation of Azelaic Acid
10 105 115	11 12 2010	Process for the Preparation of
10,125,115	11-13-2018	Efinaconazole
10,138,190	11-27-2018	Process for Preparation of Ospemifene
10,138,206	11-27-2018	Amorphous Form of Lomitapide Mesylate

Application Serial No.	Filing Date	Title
15/754,067	02-21-2018	Process for the Preparation of Apremilast
16/070,002	07-13-2018	Process for the Preparation of Tavaborole